

SHREE GANESH BIO-TECH(INDIA)LIMITED

L70101WB1982PLC121196

Reg. Office: 29, N .C., NEW ALIPORE, BLOCK – B, KOLKATA- 700053, WB, INDIA
E Mail: shreeganeshbiotechindia@gmail.com

Date: 14th February, 2017

To,
Listing Department,
BSE Limited,
P J Tower, Dalal Street
Mumbai-400001

To,
Listing Department,
The Calcutta Stock Exchange Limited,
7, Lyons Range,
Kolkata – 700 001

Scrip Code: 539470
Scrip Name: Shree Ganesh Biotech (India) Ltd

Scrip Code: 29221

Dear Sir/Madam,

Sub: Un-Audited Financial Result quarter ending 31st December, 2016 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015


In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today, 14th February, 2017 inter alia, considered and approved the Unaudited Financial Result of the company for the quarter and Nine Months ended 31st December, 2016. A copy of the same is attached herewith for your information and record.

We are also enclosing herewith Limited Review Report on Unaudited Financial Result of the company for the quarter and Nine Months ended 31st December, 2016.

Kindly take the same on your record and oblige.

Thanking you.

Yours faithfully,
For, Shree Ganesh Bio-Tech (India) Limited


Anil Chandulal Mistry
Director
DIN: 00059558



Limited Review Report

Review Report To
The Board of Directors of
SHREE GANESH BIO TECH INDIA LIMITED

We have reviewed the accompanying statement of unaudited financial results of SHREE GANESH BIO TECH INDIA LIMITED ("The Company") for the quarter and nine months ended December 31, 2016 submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial information performed by the Independent Auditor of the entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: VADODARA
Date: 14.02.2017



For Bipin & Co.
Chartered Accountants
FRNo.: 101509W


(CA Amit Shah)
Partner
M. No.: 126337

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN : L70101WB1982PLC121196

Registered Office: 29, N.C. NEW ALIPORE, BLOCK - B KOLKATA WB 700053 IN

UNAUDITED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED 31ST DECEMBER, 2016

PART - 1		(RS. IN LAKH)					Previous Year Ended
SR. NO.	Particulars	3 Months ended	Preceding 3 months ended	Corresponding 3 months ended in previous	Year to date figures for the current period ended 31/12/16	Year to date figures for the previous period ended 31/12/15	
		31.12.2016	30.09.2016	31.12.2015			31.03.2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	a) Net Sales / Income from Operations (Net of Excise Duty)	255.40	302.26	81.06	605.80	84.26	211.91
	b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from operations (net)	255.40	302.26	81.06	605.80	84.26	211.91
2	Expenses						
	a. Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00
	b. Purchase of Traded Goods	5.10	8.73	2.54	27.89	3.36	5.45
	c. Changes in inventories of finished goods, work-in-progress and stock -in-trade	0.50	0.97	25.70	(3.06)	14.80	94.35
	d. Employee benefits expense	3.21	2.63	3.99	8.48	13.10	16.81
	e. Depreciation and Amortisation expense	0.00	0.00	0.00	0.00	0.00	7.36
	f. Other Expenses	139.45	107.01	5.36	251.76	21.04	29.32
	Total Expenses	148.26	119.34	37.59	285.07	52.30	153.29
3	Profit / (Loss) from Operations before other income, finance costs and exceptional items (1 - 2)	107.14	182.92	43.47	320.73	31.96	58.62
4	Other Income	0.00	0.00	0.00	0.00	3.63	3.63
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	107.14	182.92	43.47	320.73	35.59	62.25
6	Finance Costs	1.12	1.27	1.88	3.90	5.72	7.21
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	106.02	181.65	41.59	316.83	29.87	55.04
8	Exceptional Items - Expenditure/(Income)	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary Activities before tax (7 ± 8)	106.02	181.65	41.59	316.83	29.87	55.04
10	Tax Expense: Current	0.00	0.00	0.00	0.00	0.00	1.12
	: Deffered	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit / (Loss) from Ordinary Activities after tax (9 ± 10)	106.02	181.65	41.59	316.83	29.87	53.92
12	Extraordinary items (Net of Tax expense Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11 ± 12)	106.02	181.65	41.59	316.83	29.87	53.92
14	Paid-up Equity Share Capital (Face Value Re. 10/- each) (In Rs)	183.12	183.12	183.12	183.12	183.12	183.12
15	Reserves Excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	294.47
16	Earning Per Share (before extraordinary items - not annualised)						
	(a) Basic	5.79	9.92	2.27	17.30	1.63	2.94
	(b) Diluted	5.79	9.92	2.27	17.30	1.63	2.94
17	Earning Per Share (after extraordinary items - not annualised)						
	(a) Basic	5.79	9.92	2.27	17.30	1.63	2.94
	(b) Diluted	5.79	9.92	2.27	17.30	1.63	2.94

Notes:

- The above results have been taken on record in the meeting of the Board of Directors of the Company held on 14.02.2017
- Since majority of the assets are located in one place and most of the expenses are of common nature, the management has decided not to bifurcate the results and capital employed segment wise on the basis of estimations.
- Previous period figures have been regrouped wherever considered necessary.

Place : Mumbai
Dated : 14.02.2017

For SHREE GANESH BIOTECH (INDIA) LIMITED

